Today we are going to be talking about MindMed’s, (MNDM : NASDAQ), (MMED : NEO) patent application made in collaboration with BioXcel Therapeutics.
BioXcel is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology.
The Patent is “for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour”.
Enjoy the episode!
Follow us on social media! 🙌
Want to collaborate? Send us an email at:
Video editing: @themyaholy
Check out our Benziga discounts
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#mindmed #mmed #mnmdstock
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.